Year-end report, May–April 2021/22
Back to growth with a strong finish of the quarter
The strong demand for radiotherapy solutions continued in the fourth quarter and installation volumes came in higher than last year driving revenue growth and sequential margin improvements. We also continued to form important partnerships across the cancer care ecosystem. I am proud that we have delivered order and revenue growth for the full year despite the pandemic and recent geopolitical-related challenges.
Gustaf Salford
President and CEO
Fourth quarter
• Gross order intake amounted to SEK 5,897 M (5,379), corresponding to a 2 percent increase in constant exchange rates
• Net sales were SEK 4,239 M (3,667), corresponding to a 5 percent increase in constant exchange rates
• Gross margin amounted to 37.0 percent (38.5)
• EBIT amounted to SEK 570 M (545), corresponding to an EBIT margin of 13.4 percent (14.9)
• Earnings per share was SEK 1.09 (0.89) before/after dilution
• Cash flow after continuous investments amounted to SEK 623 M (818)
Full year
• Gross order intake amounted to SEK 18,364 M (17,411), corresponding to a 4 percent growth in constant exchange rates
• Net sales were SEK 14,548 M (13,763), corre-sponding to a 4 percent increase in constant exchange rates
• Gross margin amounted to 37.4 percent (40.8)
• EBIT amounted to SEK 1,643 M (1,906), corre-sponding to an EBIT margin of 11.3 percent (13.9)
• Earnings per share was SEK 3.02 (3.28) before/after dilution
• Cash flow after continuous investments amounted to SEK 450 M (1,706)
Significant events after the quarter
• The Board of Directors proposes a dividend of SEK 2.40 (2.20) per share (paid in two installments) for the fiscal year 2021/22
• On May 6, Elekta launched new radiosurgery system: Elekta Esprit
| Group summary | Q4 | Full year | ||||||
| SEK M | 2021/22 | 2020/21 | Δ | 2021/22 | 2020/21 | Δ | ||
| Gross order intake | 5,897 | 5,379 | 2% | 3 | 18,364 | 17,411 | 4% | 3 |
| Net sales | 4,238 | 3,667 | 5% | 3 | 14,548 | 13,763 | 4% | 3 |
| Gross margin | 37.0% | 38.5% | -1.5 ppts | 37.4% | 40.8% | -3.4 ppts | ||
| EBIT | 570 | 545 | 4% | 1,643 | 1,906 | -14% | ||
| EBIT margin | 13.4% | 14.9% | -1.5 ppts | 11.3% | 13.9% | -2.6 ppts | ||
| Cash flow 1 | 623 | 818 | -24% | 450 | 1,706 | -74% | ||
| Earnings per share, SEK 2 | 1.09 | 0.89 | 22% | 3.02 | 3.28 | -8% | ||
1 After continuous investments.
2 Before / after dilution.
3 Based on constant exchange rates.
# # #
For further information, please contact:
Tobias Hägglöv, CFO
Tel: +46 76 107 4799, e-mail: [email protected]
Time zone: CET: Central European Time
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: [email protected]
Time zone: CET: Central European Time
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 120 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.